CNS Pharmaceuticals Q2 Earnings: $6.42 EPS vs. $-4,049.20 Last Year

CNS Pharmaceuticals reported Q2 EPS of ($6.42) vs. ($4,049.20) last year. CEO John Climaco emphasized the company's focus on science and urgency to improve patient outcomes. CNS is progressing towards a Phase 2 study for TPI 287 in GBM by H1 2026.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) has released its second-quarter 2025 financial results, showing a net loss of $2.4 million, a slight improvement from the $2.5 million loss reported in the same period last year. The company's CEO, John Climaco, emphasized the company's focus on science and urgency to improve patient outcomes.

The company's research and development (R&D) expenses increased to $1.2 million from $1.1 million, primarily due to preparations for a TPI 287 trial. General and administrative expenses decreased to $1.2 million from $1.4 million, thanks to lower legal, travel, and stock-based compensation expenses. As of June 30, 2025, CNS Pharmaceuticals had $12.1 million in cash, sufficient to fund operations into the second half of 2026.

CNS Pharmaceuticals' lead candidate, TPI 287, is an abeotaxane designed to cross the blood-brain barrier, showing promising results in Phase 1 trials for glioblastoma multiforme (GBM). The drug achieved 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients when combined with bevacizumab. The company plans to initiate a Phase 2 study in the first half of 2026 and engage with the FDA on study design in 2025.

CNS Pharmaceuticals has reported stable financial position with $12.1M cash runway while advancing TPI 287 for glioblastoma toward Phase 2 in 2026 [1].

References:
[1] https://www.stocktitan.net/news/CNSP/cns-pharmaceuticals-reports-second-quarter-2025-financial-results-drl8vd9udaii.html
[2] https://www.citybuzz.co/2025/08/15/cns-pharmaceuticals-inc-advances-tpi-287-toward-phase-2-gbm-trial-amid-improved-q2-2025-financials/